Clinical Trials

Positive early human safety data for its lead drug and new candidates for Rett syndrome and MASH signal a pivotal year for ProQR's Axiomer technology.

The Spanish epigenetics leader will showcase its advanced CNS and oncology pipeline at key January conferences, seeking partners and investor validation.

With a key FDA meeting set, Trevi Therapeutics pushes its drug Haduvio into late-stage trials, offering hope for millions with no approved treatments.

Pharma giant Bayer partners with biotech innovator Soufflé to develop a groundbreaking siRNA therapy, aiming to deliver genetic medicine directly to the heart.

After success in Europe, Allotex gets FDA nod to begin U.S. trials for its tissue-based presbyopia treatment, offering new hope for millions.

A routine prenatal screen can now detect a virus that causes birth defects, offering a path to prevention and sparking calls to change medical guidelines.

As it marks 32 years, Alexandria Real Estate Equities proves its resilience, dominating the market it created amid industry-wide headwinds.

Hoth Therapeutics files patents for a therapy to mitigate severe skin reactions from cancer treatments, a strategic move that could transform patient care.

Setrusumab, a promising drug for Osteogenesis Imperfecta, failed to reduce fractures in key trials, triggering a market collapse and strategic overhaul.

Pharma giant GSK partners with biotech CAMP4, leveraging novel RNA-boosting tech to develop new therapies for neurodegenerative and kidney diseases.

The neuro-focused biotech just acquired a late-stage cancer drug, securing massive funding. Is this a brilliant diversification or a high-stakes gamble?

A Phase 1 trial for Moleculin's WP1066 shows encouraging safety and anti-tumor activity for children with deadly brain tumors like DIPG.

A new study reveals a tissue allograft, AmchoPlast™, triples healing rates for diabetic foot ulcers, offering a major breakthrough for a common complication.

As Spruce Biosciences preps its rare disease drug for FDA review, the addition of a commercial veteran signals a high-stakes shift from R&D to market.

A new drug for a leading cause of blindness missed its primary goal, yet its unique ability to improve vision offers new hope for millions of patients.

With FDA alignment for its pivotal Phase 3 trial, Oncolytics Biotech is poised to bring the first immunotherapy to the challenging pancreatic cancer landscape.

After a decade of failed trials, a new drug shows promise in treating resistant lung cancer by reawakening the immune system and halting its spread.

BridgeBio Oncology's new drug candidate BBO-10203 could redefine cancer therapy by avoiding a key toxicity, unlocking a vast market.

A Chinese biotech is pioneering next-gen cancer drugs that promise higher precision and fewer side effects. Is this the future of oncology treatment?

Century Therapeutics adds M&A and investment heavyweights to its board, a strategic move to navigate the clinical gauntlet with its iPSC-derived diabetes cure.